247 related articles for article (PubMed ID: 21463227)
1. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.
Godtman R; Holmberg E; Stranne J; Hugosson J
Scand J Urol Nephrol; 2011 Sep; 45(4):226-32. PubMed ID: 21463227
[TBL] [Abstract][Full Text] [Related]
2. Reliability of death certificates in prostate cancer patients.
Fall K; Strömberg F; Rosell J; Andrèn O; Varenhorst E;
Scand J Urol Nephrol; 2008; 42(4):352-7. PubMed ID: 18609293
[TBL] [Abstract][Full Text] [Related]
3. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
van Leeuwen PJ; Otto SJ; Kranse R; Roobol MJ; Bul M; Zhu X; de Koning H; Schröder FH
BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
[TBL] [Abstract][Full Text] [Related]
4. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995.
Albertsen PC; Walters S; Hanley JA
J Urol; 2000 Feb; 163(2):519-23. PubMed ID: 10647669
[TBL] [Abstract][Full Text] [Related]
5. Ascertaining cause of death among men in the prostate cancer intervention versus observation trial.
Barry MJ; Andriole GL; Culkin DJ; Fox SH; Jones KM; Carlyle MH; Wilt TJ
Clin Trials; 2013; 10(6):907-14. PubMed ID: 23988464
[TBL] [Abstract][Full Text] [Related]
6. Assessment of causes of death in a prostate cancer screening trial.
Mäkinen T; Karhunen P; Aro J; Lahtela J; Määttänen L; Auvinen A
Int J Cancer; 2008 Jan; 122(2):413-7. PubMed ID: 17935123
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
8. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
9. Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
Bergdahl AG; Aus G; Lilja H; Hugosson J
Cancer; 2009 Dec; 115(24):5672-9. PubMed ID: 19813273
[TBL] [Abstract][Full Text] [Related]
10. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
12. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
16. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
[TBL] [Abstract][Full Text] [Related]
17. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
18. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
19. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
[TBL] [Abstract][Full Text] [Related]
20. [Screening for early detection of prostate cancer (first experience in Israel)].
Neheman A; Shotland Y; Metz Y; Stein A
Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]